» Authors » Margherita Carboni

Margherita Carboni

Explore the profile of Margherita Carboni including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 162
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Schinke H, Fornvik Jonsson M, Gummesson M, Nilsson R, Gaupp S, Manuilova E, et al.
Clin Chem Lab Med . 2025 Mar; PMID: 40068924
Objectives: The Apollo study was designed to support the clinical performance verification of the adjusted cutoffs of the Elecsys β-Amyloid(1-42) (Aβ) cerebrospinal fluid (CSF) II, β-Amyloid(1-40) (Aβ) CSF, Phospho-Tau (181P)...
2.
Anastasi F, Fernandez-Lebrero A, Ashton N, Ortiz-Romero P, Torres-Torronteras J, Gonzalez-Escalante A, et al.
Alzheimers Dement . 2025 Feb; 21(2):e14609. PMID: 39998475
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from...
3.
Ritchie C, Blennow K, Gispert J, Johnson S, van Maurik I, Vermunt L, et al.
Front Neurosci . 2024 Jul; 18:1339742. PMID: 38994272
No abstract available.
4.
Panyard D, Reus L, Ali M, Liu J, Deming Y, Lu Q, et al.
Alzheimers Dement . 2024 May; 20(7):5044-5053. PMID: 38809917
Introduction: Recent genome-wide association studies (GWAS) have reported a genetic association with Alzheimer's disease (AD) at the TNIP1/GPX3 locus, but the mechanism is unclear. Methods: We used cerebrospinal fluid (CSF)...
5.
Palpatzis E, Akinci M, Aguilar-Dominguez P, Garcia-Prat M, Blennow K, Zetterberg H, et al.
Ann Neurol . 2024 Mar; 95(6):1058-1068. PMID: 38466157
Objective: Along with the known effects of stress on brain structure and inflammatory processes, increasing evidence suggest a role of chronic stress in the pathogenesis of Alzheimer's disease (AD). We...
6.
Roccati E, Bindoff A, Collins J, Eastgate J, Borchard J, Alty J, et al.
Front Aging Neurosci . 2024 Feb; 16:1346214. PMID: 38384935
Introduction: Modifiable risk factors account for a substantial proportion of Alzheimer's disease (AD) cases and we currently have a discrete AT(N) biomarker profile for AD biomarkers: amyloid (A), p-tau (T),...
7.
Suridjan I, van der Flier W, Monsch A, Burnie N, Baldor R, Sabbagh M, et al.
Alzheimers Dement (Amst) . 2023 Dec; 15(4):e12508. PMID: 38058357
Introduction: Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non-invasive blood-based biomarker (BBBM) test for detection of amyloid-β pathology may reduce diagnostic barriers and facilitate DMT...
8.
Hale M, Langhough R, Du L, Hermann B, Van Hulle C, Carboni M, et al.
Neurobiol Aging . 2023 Nov; 133:87-98. PMID: 37925995
Neuropsychological measures sensitive to decline in the preclinical phase of Alzheimer's disease are needed. We previously demonstrated that higher amyloid-beta (Aβ) assessed by positron emission tomography in adults without cognitive...
9.
Blennow K, Galasko D, Perneczky R, Quevenco F, van der Flier W, Akinwonmi A, et al.
Alzheimers Dement . 2023 Sep; 19(12):5805-5816. PMID: 37694991
Introduction: Many people with cognitive complaints or impairment never receive an accurate diagnosis of the underlying condition, potentially impacting their access to appropriate treatment. To address this unmet need, plasma...
10.
Pelkmans W, Shekari M, Brugulat-Serrat A, Sanchez-Benavides G, Minguillon C, Fauria K, et al.
Alzheimers Dement . 2023 Sep; 20(1):483-493. PMID: 37690071
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired...